The differences in serum levels of Gal-9, sTIM-3, FAPB1, and FABP4 between RA patients with none-to-mild and moderate-to-severe NAFLD. The gene discussed is LGALS9; the disease is metabolic dysfunction-associated steatotic liver disease.